Here are the DEF 14A proxy statements from MaxCyte, Inc. (MXCT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MXCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MXCT filings page.
MaxCyte, Inc. is asking stockholders to elect three Class II directors—Patrick Balthrop, Cynthia Collins, and Stanley Erck—to serve until the 2029 annual meeting, and to ratify CohnReznick LLP as independent auditor for the year ending December 31, 2026.
The 2026 annual meeting will be held on June 17, 2026 at 11:00 a.m. Eastern Time in Rockville, Maryland, for holders of 107,121,672 common shares outstanding as of April 21, 2026. The board reports that eight of nine directors are Nasdaq‑independent and is led by an independent non‑executive chair, Richard Douglas.
For 2025, CEO Maher Masoud received total compensation of $2,687,657, including salary, equity awards, and an annual bonus funded at 88.5% of target, based on goals tied to revenue, EBITDA and operational milestones. Major stockholders include Capricorn Fund Managers (7.7%), BlackRock (6.5%), and River Global Investors (5.1%).